Learn · Research use only

Are Peptides Safe? What the Science and Regulations Say

By BioLabs Research · Last reviewed October 2026

A factual overview of how the safety of a peptide is established, what regulators have published, and why purity and documentation matter in research.

"Are peptides safe?" has no single answer, because "peptides" covers an enormous class of molecules: from insulin, a regulated medicine, to research compounds that have never been evaluated in people. Safety is a property of one specific molecule, made to a specific quality, in a specific context. It is not a property of a chemical class.

Why there is no single answer

Peptides range from two amino acids to chains large enough to count as proteins^[1]. They differ in sequence, shape, chemical modifications and stability. Two peptides built from the same amino acids in a different order are different molecules^[2]. Knowledge about one peptide, including its safety record, therefore does not transfer to another, and data on a full-length natural molecule do not automatically apply to a fragment of it.

Three factors that decide a peptide's safety profile

• The specific compound. Insulin has been studied clinically since January 1922^[3]. Many other peptides are research tools only. Drugs@FDA, for example, lists no approved product containing BPC-157 or a thymosin^[4].
• Regulatory status. A compound's standing depends on whether a regulator has reviewed it for a specific use. FDA approval attaches to a specific drug product^[5], so it does not extend to a different molecule.
• Purity and quality. Synthetic peptides can carry deletion sequences, oxidized residues, residual counter ions and degradation products^[6], so the quality of a particular lot matters.

How safety is established for a medicine

In the United States, a previously untested drug enters human testing under an investigational new drug application, and that clinical investigation is generally divided into three phases^[7]:

• Phase 1 is the first introduction into humans, usually 20 to 80 subjects, and studies how the drug is handled by the body and its pharmacological actions^[7].
• Phase 2 consists of controlled studies, usually involving no more than several hundred patients, that evaluate effectiveness for a particular indication and identify common short-term risks^[7].
• Phase 3 expands to several hundred to several thousand subjects to gather the additional information on effectiveness and safety needed to evaluate the overall benefit-risk relationship^[7].

A new drug cannot be introduced into interstate commerce without an effective FDA approval^[5], and that approval follows FDA's review of the clinical evidence. Frequent appearance in the research literature is not a substitute: laboratory and animal findings describe what was observed in those systems, not whether a compound is safe in people.

What FDA has published about unapproved peptides

When FDA reviews bulk substances nominated for use by compounding pharmacies, it publishes the potential significant safety risks it identifies^[8]. For several peptides, FDA's descriptions cite a risk of immunogenicity (an unwanted immune response) for certain routes, complexities with peptide-related impurities and characterization of the active ingredient, and too little safety information to know whether the substance would cause harm in humans^[8]. BPC-157, the TB-500 fragment (LKKTETQ) and AOD-9604 are among the peptides FDA lists with these descriptions; their nominations were withdrawn by the nominators, and FDA's page keeps the safety-risk language^[8].

Purity and impurities

Most peptides today are made by solid-phase peptide synthesis^[6]. A review of peptide-related impurities describes several families: deletions and insertions of amino acids, racemized residues, leftover protecting groups, oxidation of side chains, dimers and larger aggregates, trifluoroacetate and other counter ions, and degradation products such as diketopiperazines, pyroglutamate and succinimide forms^[6]. The review notes that such impurities can distort early functional studies and lead to erroneous conclusions^[6]. For research, a purity figure is only meaningful when it is tied to a lot, a method and a stated detection wavelength.

Third-party testing and batch COAs

A certificate of analysis (COA) is a document for one manufacturing lot. It should name the laboratory and the test date and record identity, usually by mass spectrometry, and purity, usually as HPLC area percent at a stated wavelength. When a COA is described as third-party, the testing laboratory should be independent of both the manufacturer and the seller. A certificate covers only the lot printed on it.

Whatever its source, a COA is only useful if its lot number matches the vial label and the packing slip. Lot COAs are available on request and are being added to our COA library, and how to read a peptide COA explains each field.

Handling and storage as laboratory materials

Research peptides are chemical reagents and are handled under ordinary laboratory practice. The safety data sheet (SDS) is the reference for each material: each of our SDSs states the storage temperature for the lyophilized solid, which differs by compound, and each specifies the original sealed vial, protected from light and moisture. Download each one from the SDS library.

• Keep materials in labeled, sealed containers in a designated laboratory area, separate from food and personal items.
• Record the lot number of every vial so results can be traced back to its COA.
• Use the personal protective equipment and disposal routes named in the SDS and in your laboratory's chemical hygiene plan^[9].

Background on what peptides are is in What are peptides?; the chemistry and legal questions are covered in are peptides steroids? and are peptides legal?.

Our position

BioLabs Research supplies all compounds strictly for laboratory research use only. Our products are not drugs and are not for human or veterinary use, and we make no claims about safety, effectiveness or any use in people or animals. Product pages such as BPC-157 and TB-500 list identity data and SDS links only.

Frequently asked questions

Are peptides safe?

There is no single answer. Safety belongs to a specific molecule, at a specific quality, evaluated for a specific use. Only clinical trials and regulatory review can establish that a compound is safe for use in people.

Are research peptides FDA approved?

Research-use-only compounds are not approved drugs. FDA approval applies to a specific drug product and does not transfer to other molecules.

What has FDA said about peptides such as BPC-157 and TB-500?

FDA's page on bulk substances for compounding describes potential risks for these peptides, including immunogenicity, impurity and characterization complexities, and insufficient human safety information. Their nominations were withdrawn and FDA kept that language on the page.

Why does purity matter in peptide research?

Synthetic peptides can contain deletion sequences, oxidized residues, counter ions and degradation products. These can distort laboratory results, so purity must be tied to a lot, a method and a wavelength.

What should a batch COA show?

The lot number, the testing laboratory and test date, an identity result such as mass spectrometry, and purity as HPLC area percent at a stated wavelength. The lot number must match the vial label.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement, and not intended to diagnose, treat, cure or prevent any condition. Nothing on this page is medical or legal advice.

References

1. National Library of Medicine. MeSH descriptor D010455, Peptides (scope note). meshb.nlm.nih.gov/record/ui?ui=D010455
2. Sanvictores T, Farci F. Biochemistry, Primary Protein Structure. In: StatPearls. StatPearls Publishing; updated 2025. PMID 33232013. pubmed.ncbi.nlm.nih.gov/33232013
3. US Food and Drug Administration, FDA History Office. 100 Years of Insulin. www.fda.gov/about-fda/fda-history-exhibits/100-years-insulin
4. US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (database). www.accessdata.fda.gov/scripts/cder/daf
5. 21 U.S.C. 355(a), necessity of effective approval of a new drug application (US Code, GovInfo). www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec355.htm
6. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012. PMID 25044089. pubmed.ncbi.nlm.nih.gov/25044089
7. 21 CFR 312.21, phases of an investigation (eCFR). www.ecfr.gov/current/title-21/section-312.21
8. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
9. 29 CFR 1910.1450, occupational exposure to hazardous chemicals in laboratories: Chemical Hygiene Plan (eCFR). www.ecfr.gov/current/title-29/section-1910.1450